Jeil's new drug candidate JP-1366 for GERD has been approved for phase 3 clinical trials and is speeding up commercialization.

Currently, sales of HK inno.N's P-CAB-based new drug K-Cab are high in Korea.
On the 14th, the MFDS approved a phase 3 clinical trial plan for JP-1366 applied by Onconic Theapeutics, a subsidiary of Jeil Pharmaceutical. This clinical trial is a randomized, double-blind, parallel design, activity contrast, non-isomeric, multi-organ phase 3 clinical trial that compares and evaluates the efficacy and safety of JP-136620 mg or Esomeprazole 40 mg administration in erosive esophagitis patients.

JP-1366 is a treatment for gastroesophageal reflux disease in the P-C